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Women who harbor mutations in breast cancer susceptibility genes are at an increased 
lifetime risk of developing breast cancer and are faced with decisions about managing their risks, 
including the decision of whether to undergo a risk reducing mastectomy (RRM). While decision 
making for risk management has been studied extensively for BRCA1 and BRCA2 carriers, there 
is much less information surrounding risk management for women with mutations in moderate 
penetrance genes. This is a retrospective study of 280 women undergoing genetic counseling at a 
Los Angeles-based academic hospital between 2009 and 2019. The study used medical records 
to examine rates of RRMs in both affected and unaffected women with 1) no known mutation 
(N=92), 2) a mutation in a moderate penetrance gene CHEK2, ATM, NBN, or PALB2 (N=90), or 
3) a BRCA mutation (N=98). Participants had a mean age of 45.7 years and were 78% Caucasian, 
34% affected with breast cancer, and 31% never married. Results showed that mutation status 
was associated with RRM decision (p<.001), with 8.6% (8/92) of women with no known risk 
mutations, 30% (27/90) of moderate penetrance gene carriers, and 39.8% (39/98) of BRCA 
mutation carriers undergoing RRM. Women were more likely to undergo RRM if they were 
affected with breast cancer (p<.001), had a younger age at diagnosis (p<.001), were presented 
with a higher lifetime risk (p=.006), and were married or partnered (p=0.02). Participants with a 
moderate risk mutation without breast cancer were more likely to have RRM if they had a first 
degree relative with breast cancer (p=.03). The NCCN Guidelines® does not typically 
recommend consideration of RRM for moderate penetrance carriers, but their rates of RRM 
approach those of BRCA carriers. Genetics providers must better equip surgeons and patients 
with knowledge of risks associated with moderate penetrance mutations, and healthcare 
providers must strive to understand why surgical decisions are made. 
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Breast cancer is the most common female cancer worldwide and the second most 
common cancer overall (Rojas, 2016; Ullah, 2019). While most breast cancers are sporadic, 
hereditary cancers comprise approximately 5-10% of all breast cancer cases (Genetics of Breast 
and Gynecologic Cancers, 2020). These hereditary cancers are largely caused by inherited 
single-gene mutations in tumor suppressor genes. The most common genes involved in 
hereditary breast (and ovarian) cancer syndromes are BRCA1 and BRCA2, which were 
discovered in the mid-1990s and remained synonymous with hereditary breast cancer until 
recently (Familial Breast Cancer, 2001). Mutations in BRCA1 and BRCA2 are considered “high 
penetrance” because they confer, by some estimates, over an 80% lifetime risk for female breast 
cancer. Mutations in these two genes account for just half of all hereditary breast cancers 
(Easton, 1999; Easton, 2015; Kapoor, 2015; Kuchenbaecker 2017; Tedaldi, 2017). Other gene 
contributors to hereditary breast cancer remained largely unidentified until the past decade, as the 
advent and implementation of next-generation DNA sequencing brought the possibility of 
simultaneous analysis of multiple newly-discovered genes implicated in hereditary cancers 
(Powers, 2018). These genes include “moderate penetrance” breast cancer susceptibility genes 
such as ATM, CHEK2, NBN, and PALB2, which are generally estimated to have a 23-43%, or 2-
4 fold increased lifetime risk of female breast cancer (Antoniou, 2014, Easton, 2015; LaDuca, 
2020; Leedom, 2016; Marabelli, 2016).  
For women who are considered at higher risk for breast cancer, such as gene mutation 
carriers, current risk management options include screening, chemoprevention, risk reducing 
mastectomy (RRM), and controversially, prophylactic oophorectomy (Domchek 2006; Jatoi, 
2016; Jernstrom, 2004; Kotsopoulos 2018). Unaffected women are therefore left with few non-
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invasive options to consider when presented with a significant lifetime risk. Women who have 
been diagnosed with breast cancer also decide whether their surgical approach entails removing 
1) solely the affected area of the breast or 2) the entire breast with the cancer or 3) additionally 
removing the contralateral breast to reduce the risk of a new primary breast cancer. The most 
risk-conservative, efficacious, and invasive procedure indicated for women at a high risk of 
breast cancer is the RRM, which reduces breast cancer risk for BRCA1/2 carriers by 90-95% 
(Domchek, 2010; Singh, 2013). 
Decision making for RRMs requires comprehension of both the efficacy of the procedure 
and the adverse events and risks involved (Scott, 2013).  While decision making for risk 
management has been studied for BRCA1 and BRCA2 carriers, there is a paucity of information 
surrounding risk management for women with moderate penetrance genes such as ATM, CHEK2, 
NBN, and PALB2. There are many factors at play during the RRM decision making process. In 
this manuscript, we assess whether the number of first, second, and third degree relatives with a 
history of breast cancer influences the likelihood of undergoing a RRM among a) women with 
mutations in the moderate penetrance genes (ATM, CHEK2, NBN, and PALB2), b) women with 
BRCA1 and BRCA2 mutations, and c) women with no known mutations. We also explore 
whether the decision regarding RRMs in these three genetic-risk-stratified groups depends on 
patient age and marital status. Our study population of 280 women includes both women who 
have and who have not been diagnosed with breast cancer. For women who have not been 
diagnosed, we investigate whether the estimated remaining lifetime risk presented to them at the 
time of genetic testing influences their decision-making for RRM. 
 
  





A. Breast Cancer Screening and Risk Reduction Options 
 
While breast cancer is one of the most common cancers, it ranks fifth in cancer mortality due 
to its relatively favorable prognosis compared to other cancer types (Ullah, 2019). Population 
screening for unaffected women and the tailoring of these screening methods to women based on 
their lifetime risks contributes to breast cancer’s relatively favorable prognosis. Women without 
signs or symptoms undergo breast screening so that if a cancer does develop, it can be detected 
and treated at an early stage. The etiology of breast cancer is multifactorial and can be caused by 
genetic as well as environmental factors. Some lifestyle factors that may also contribute to a 
women’s lifetime risk for developing breast cancer include combined estrogen/progesterone 
therapy for more than three to five years, alcohol consumption, lack of exercise, excess weight, 
and not breastfeeding (NCCN v.1.2020). A number of these lifestyle factors are used in 
conjunction with age and family history to generate an estimated lifetime risk for women who 
have no known gene mutation using empirical risk models, such as the Tyrer-Cuzick model 
(Stevanato, 2019).  
Women who are identified as having a higher risk secondary to her family history, gene 
mutation, lifestyle, or very early age of onset of breast or ovarian cancer, may be offered 
additional screening options. NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines®) are the gold standard for the treatment and management of an array of cancers, 
including recommendations for detection, prevention, and risk reduction. The NCCN 
Guidelines® for Breast Cancer Screening and Diagnosis state that screening modalities depend 
on age, medical history, and family history. Screening may include “breast awareness, regular 
clinical encounters, clinical breast exam, breast imaging with screening mammography, and in 
selected cases, breast MRI” (NCCN, v1.2020). 
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The NCCN Guidelines® offer information on risk reduction for breast cancer and 
recommend that women at an increased risk for developing breast cancer receive genetic 
counseling. Risk reducing chemoprevention such as aromatase inhibitors or tamoxifen may be 
considered and discussed based on the woman’s age, potential contraindications, and associated 
adverse effects. Finally, the NCCN supports consideration of RRMs for women not only with 
gene mutations conferring a high risk for breast cancer such as BRCA1 or BRCA2, but also for 
women with a compelling family history or possibly for women with prior thoracic radiation 
therapy at or before age 30. The NCCN also offers gene-specific management guidelines which 
are delineated in subsequent sections of this background. 
 
B. Surgical Approaches and Management for Breast Cancer Patients 
Surgical treatment for breast cancer has been studied extensively. The radical mastectomy, or 
the removal of the breast containing the cancer and the underlying pectoral muscle, was 
considered the standard of care from the 1950s to the 1970s, until it was challenged by emerging 
breast conservation strategies in combination with other approaches including radiation, 
chemotherapy, and endocrine therapy (Lerner, 2001). In 1990, the National Institute of Health 
(NIH) Consensus conference established that “breast conservation treatment…is preferable 
because it provides survival equivalent to total mastectomy…while preserving the breast” (NIH, 
1990). Since then multiple randomized controlled trials have shown that breast conservation 
strategies such as lumpectomy with radiation result in similar local recurrence and survival 
outcomes to invasive techniques such as the radical mastectomy (Beaulieu, 1998; Fisher, 2002).  
Today, women with unilateral breast cancer have options regarding surgical treatment, both 
for the affected breast and for the contralateral, unaffected breast. Contralateral prophylactic 
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mastectomy (CPM) is the removal of the unaffected breast in breast cancer patients and remains 
a choice for women who wish to decrease the risk of developing contralateral breast cancer 
(CBC) (Herrington, 2005). There are two groups that are at a substantially increased risk for 
contralateral breast cancer development: women with BRCA1/2 mutations and women with a 
history of mantle radiation during childhood and adolescence (Metcalfe, 2004). The role of CPM 
is generally accepted for BRCA1/2 carriers, but the benefit is not evident in women who are 
diagnosed with breast cancer at early ages but do not carry a mutation or those who have a strong 
family history but no known mutation (Teoh, 2020). For women with BRCA1/2 mutations, CPM 
reduces the risk of CBC by over 90% (Li, 2016; van Sprundel, 2005). Studies also show that 
CBC rates are higher for women who have a positive family history of breast cancer and are 
stratified by degree of relation (Bernstein, 1992; Boughey, 2010; Ji, 2007; Kuchenbaecker, 2017; 
Narod, 2016;  Reiner, 2018; Teoh, 2020; Vaittinen, 2000). Decision-making for surgical 
approach for breast conservation surgery (BCS), i.e. unilateral mastectomy or lumpectomy, 
versus CPM is discussed in a subsequent section of this background. 
 
C. Breast Cancer Risks for Women with BRCA1/2 Mutations 
 
As mentioned, breast cancer screening, risk reduction, and surgical decision making are often 
considered in the context of a woman’s lifetime risk for breast cancer. A woman’s lifetime risk 
for breast cancer may be most drastically affected by germline mutations in genes that function 
to prevent the development of cancer. i.e. tumor suppressor genes. Cancer genetics is a relatively 
new field within genetic counseling, but if there is any gene that spearheaded its push into its 
current paradigm, it’s BRCA1. Mary-Claire King et al began to link early-onset familial breast 
cancer to chromosome 17q21 in 1990. They localized the BRCA1 gene in 1991, then mapped 
BRCA1 in 1993, and isolated and sequenced BRCA1 in 1994, thus making it the first cloned 
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hereditary cancer susceptibility gene known to mankind (Anderson, 1993; Friedman, 1994; Hall, 
1990; King, 1991, 1993; Miki, 1994). In 1995, scientists at the National Institutes of Health 
(NIH) discovered the prevalence of this gene in the general Ashkenazi Jewish population at a 
frequency of 1% (FitzGerald, 1996). Subsequent studies implicated BRCA1 in coding for tumor 
suppressors, though its molecular mechanism remained unknown (Jensen, 1996). By 1998, 
researchers had shown that BRCA1 and BRCA2 coexist in a protein complex, leading them to 
believe that they work in concert in the DNA repair pathway and that perturbations or mutations 
in either gene could be a cause for both breast and ovarian cancers, among other cancers (Chen, 
1998). 
Since their implication in breast cancer and other diseases, BRCA1 and BRCA2 have been the 
focus of dozens of studies that have aimed to classify the risk they each confer to an individual 
for breast cancer. In 1994, the same year that BRCA1 was discovered, researchers homed in on 
33 families with known BRCA1 linkage and found that female carriers faced an 87% percent 
chance of developing breast cancer by age 70 (Ford, 1994). Luckily, this proved to be the apex 
for breast cancer risk estimates for BRCA1 to date. Larger studies including more than 20 times 
the number of families and taking into account ethnic origin, including Ashkenazi Jewish 
ancestries, estimated the risk conferred by the BRCA1 gene to be 46%, which was ultimately 
accepted as the lowest risk estimate to date. GeneReviews takes into account the many studies 
conducted to calculate the breast cancer risks for women with BRCA1 and BRCA2 mutations and 
compiles those into a table for referencing: the risk of breast cancer in a woman with a germline 
BRCA1 pathogenic variant is 46-87%; the risk of breast cancer in a woman with a germline 
BRCA2 pathogenic variant is 38-84%; and the general population risk of breast cancer is 12% 
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(Breast Cancer Linkage Consortium 1999; Easton, 1995; Lee, 2011; Mavaddat, 2013; Rakha, 
2008; Satagopan 2001).  
One study that stands apart from the others in scope and thoroughness is Risks of Breast, 
Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. In 2017, 
Kuchenbaecker et al published prospective results estimating age-specific risks of breast and 
contralateral breast cancer for BRCA1/2 carriers and modifications of risks due to family history 
and mutation location. Out of 6036 BRCA1 female carriers and 3820 BRCA2 female carriers, 
49% were affected with either breast or ovarian cancer while 51% were unaffected during the 
duration of the study from 1997-2011. BRCA1 carriers were estimated to have a 72% chance of 
developing breast cancer by 80 while BRCA2 carriers were estimated to have a risk of 69% based 
on the data collected. This percentage risk approaches the higher end of the range previously 
defined, but researchers took their analysis a step further by analyzing risks per decade. For 
BRCA1, women’s risk increased rapidly through ages 30-40, while for BRCA2, the risk 
increased quickly through ages 40 to 50. Both genes’ conferred risks leveled off until 80 years of 
age. Not surprisingly, more affected first and second degree relatives translated into higher 
hazard ratios for women with both BRCA1 and BRCA2 mutations. Interestingly, but not 
ostensibly germane to BRCA1/2 perceived risk and management, the location of the mutation in 
both BRCA1 and BRCA2 were positively correlated with breast cancer risk (Kuchenbaecker, 
2017). Finally, a recently published study indicates that the absolute risk by age 80 for BRCA1 
and BRCA2 carriers is 75% and 76%, respectively (LaDuca, 2020). 
In the aforementioned paper, Kuchenbaecker et al also demonstrated that the cumulative risk 
for contralateral breast cancer (CBC) 20 years after the original diagnosis was 40% for BRCA1 
and 26% for BRCA2 (Kuchenbaecker, 2017). This estimate is taken in the context of previously 
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conducted studies including published data by Metcalfe et al wherein the risk of developing 
contralateral breast cancer in BRCA1/2 carriers was estimated to be approximately 40% at 10 
years (Metcalfe, 2004). A more recent study by Metcalfe et al provided BRCA1/2 gene-specific 
estimates: the 15 year risk of CBC for BRCA1 was estimated to be 36.1% and 28.5% for women 
with a BRCA2 mutation. Another retrospective study estimated the risk of CBC in BRCA1/2 
patients to be 47.4% over the course of 25 years from a woman’s first breast cancer (Graeser, 
2009). Kuchenbaecker’s study also demonstrated, in alignment with these previously conducted 
retrospective studies, that women were at a higher risk for contralateral breast cancer (CBC) 
when diagnosed before age 40 versus after age 50 (Graeser, 2009; Kuchenbaecker, 2017; 
Metcalfe, 2011). 
 
D. BRCA1/2-Specific Management Options 
Mary-Claire King, the discoverer of BRCA1, discussed a “scientific purgatory” surrounding 
the utility of genetic testing when BRCA testing was first entering the clinical realm: even if we 
could identify a woman at high risk, it was futile to intervene reliably (Bouchard, 2004; 
Holtzman, 1998; Koenig, 1998). Since then, our knowledge for reliably intervening for BRCA 
management has developed considerably. Domchek states, “there should no longer be a sense of 
nihilism about genetic testing for BRCA1/2. If we can identify the women who have these 
genetic mutations, we can improve their overall mortality with [proper] interventions” 
(Domchek, 2010; Printz, 2011).  
The diagnosis of Hereditary Breast and Ovarian Cancer Syndrome (HBOC) begins with 
offering molecular genetic testing to identify a germline pathogenic/likely pathogenic variant in 
BRCA1 or BRCA2. Following a molecular diagnosis, women should be offered follow up options 
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in accordance with current guidelines. Regarding breast cancer risk, the NCCN Guidelines® 
(v.1.2020) recommend that women who have tested positive for mutations in BRCA1/2 begin 
breast awareness at age 18, initiate clinical breast examination (CBE) every six to twelve months 
at age 25, and increase radiological screening beginning at age 25 to at least age 75 with age-
dependent frequency and age-dependent modalities including annual breast MRIs and 
mammograms. Similar to NCCN Guidelines®, GeneReviews guidelines for surveillance of 
breast cancer for women with HBOC include monthly breast self-exams, initiate CBEs every 6 
months to 1 year at age 25, yearly breast MRI beginning at age 25, and annual mammograms 
starting at age 30 (Petrucelli, 1993; updated 2016). A Dutch study set out to validate this model 
of screening based on risk group, found that screening for BRCA1 should begin at 25 years, 
screening for BRCA2 should begin at 30 years, and screening for familial risk should begin at 35 
years (Tilanus-Linthorst, 2013). Some studies suggest that more than 80% of BRCA carriers 
adhere to the commonly adopted screening methods of MRI and mammogram (Gilbert, 2017; 
Schwartz, 2012). 
Data in support of chemoprevention and prophylactic oophorectomies to reduce breast cancer 
risks for BRCA1/2 carriers is somewhat limited. In a retrospective study, King et al showed that 
tamoxifen, a selective estrogen receptive modulator (SERM), reduced breast cancer risk for 
healthy women with a hereditary BRCA1/2 mutation by 62% (King, 2001). However, there have 
been no prospective trials to test if SERMs are as effective as chemoprevention. There are other 
breast cancer risk-reducing agents including raloxifene and aromatase inhibitors. The NCCN 
offers guidelines regarding use of tamoxifen, raloxifene, and aromatase inhibitors, though they 
are not tailored specifically to BRCA1/2 mutation carriers. Only 15% of BRCA1/2 carriers are 
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offered a chemoprevention trial and just 8.5% BRCA1/2 carriers begin chemoprevention within 
the first 4 years of genetic testing results (Padamsee, 2017; Pujol, 2012). 
There are mixed reviews on whether prophylactic oophorectomies as a primary means of 
decreasing risk for ovarian cancer also decrease the risk for breast cancer (Metcalfe, 2005). 
Metcalfe et al also demonstrated that women with BRCA1/2 mutations taking tamoxifen or who 
have undergone an oophorectomy diminish their risk of developing CBC (Metcalfe, 2004). 
RRMs are a common consideration among BRCA1/2 carriers. Recent data shows that RRM 
in unaffected BRCA1 carriers is associated with lower mortality but that for unaffected BRCA2 
carriers, surveillance versus RRM led to similar survival rates (Heemskerk-Gerritsen, 2019). The 
NCCN Guidelines® state to, “discuss the option of risk-reducing mastectomy [in regard to] 
degree of protection, reconstruction options, and risks for BRCA1 and BRCA2.” Life expectancy 
and residual breast cancer risk should be considered when counseling these patients as well. 
Importantly, the NCCN Guidelines® recommend addressing psychosocial and quality-of-life 
aspects of undergoing RRM. 
 
E. Breast Cancer Risks for Families and Populations with ATM, CHEK2, NBN, and 
PALB2 Mutations 
a. Overview  
 
The distinction between moderate and high penetrance genetic risk stratification is 
defined arbitrarily, but researchers have previously defined moderate penetrance in terms of gene 
carrier cancer incidence that is two to four fold higher than in the general population (Easton, 
2015; Tung, 2016). 2-5% of those who are referred for cancer genetic testing are identified as 
carriers of moderate penetrance gene mutations (Tung, 2016). Per the National Cancer Institute, 
these moderate penetrant mutations are thought to be more frequent in the general population 
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than those conferring higher risks and are the cause for a small fraction of cancers, but a 
significant percentage of familial breast cancers (Smith, 2015). Therefore, it is paramount for 
clinicians to understand the risks conferred by moderate penetrance mutations and appropriately 
counsel patients based on those risks to ensure that women are making the most informed and 
rational decisions that best suit their circumstances. Each of the moderate penetrance genes 
discussed below—ATM, CHEK2, NBN, and PALB2—have estimates that fall within the two to 
four-fold increased lifetime risk windows, but vary in degree of breast cancer risk. 
b. ATM and breast cancer risks 
ATM is a protein kinase that functions to monitor and repair double-stranded DNA breaks 
and maintain genomic stability (Shiloh, 2003). The ATM protein was discovered as part of the 
gene that is responsible for the autosomal recessive human genetic disorder ataxia telangiectasia 
(AT), a disease characterized by cerebellar degeneration leading to progressive neuromotor 
dysfunction, immunodeficiency, genomic instability and sensitivity to ionizing radiation 
(Savitsky, 1995). Studies then began to compare the incidence of breast cancer and mortality in 
relatives of AT patients to the general population. A review of four of these studies estimated 
that the relative risk of breast cancer to be 3.9 (CI=95%, 2.1 to 7.2) (Easton, 1994; Inskip, 1999; 
Janin, 1999; Olsen, 2001; Swift, 1987; Swift, 1991; Su, 2000). Studies estimating relative risks 
for heterozygous mutations in ATM following that analysis reported a range of 2.4 to 3.4, with 
younger women experiencing a higher degree of relative risk (Easton, 1994; Geoffroy-Perez, 
2001; Olsen, 2005; Swift, 1987). Thompson et al then conducted a study congruent with these 
findings, stating that the relative risk of breast cancer for ATM carriers was 2.23 (CI=95%, 1.16 
to 4.28) but as high as 4.94 (CI=95%, 0.76 to 2.00) in women younger than 50. These findings 
confirmed a moderate penetrance risk status for ATM, but ultimately failed to support a 
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genotype-phenotype risk relationship (Thompson, 2005). The following year, Renwick et al 
published a study combining ATM truncating, splicing, and missense mutations which are 
strongly implicated in AT and found that the relative risk of breast cancer to be 2.37 (CI=95%, 
1.51 to 3.78) using a segregation analysis (Renwick, 2006). 
A meta-analysis of the three large cohort studies of family members with AT revealed 
that truncating variants are “likely moderate penetrance”, conferring a relative risk of 2.8 
(CI=90%, 2.2 to 3.7; p-value=4E-11) and a 27% absolute risk by 80 years of age (Easton, 2015). 
Approximately 70% of ATM mutations are truncating variants (Shiloh, 2003). Easton et al also 
predict that missense variants are likely to confer increased breast cancer risks (Easton, 2015). In 
fact, Goldgar et al previously demonstrated that ATM p.Val2424Gly confers higher risks than 
truncating variants (8.0; 90% CI, 2.8 to 22.5; p-value=0.0005) (Goldgar, 2011). The most recent 
study cited here estimates an odds ratio of 2.91 (N=79912, p-value=9.53E-44) for female ATM 
carriers (LaDuca, 2020). ATM mutation carrier frequency in Western populations has been 
estimated to be as high as 1% (Fitzgerald, 1997; Swift, 1986). 
In general, the relationship between ATM variants and risk for CBC remains contentious. 
Four common variants of ATM have been demonstrated to be associated with lower CBC risk 
(RR=0.8) compared to rare, missense ATM mutations (Concannon, 2008; Teoh, 2020). Bernstein 
postulates that this can be explained by deleterious rare ATM variants acting in tandem with 
radiation exposure to increase the risk of a tumor developing (Berstein, 2017). While overall 
breast cancer risk is unknown, radiation at least appears to contribute to contralateral breast 
cancer risk (Broeks, 2008). 
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c. CHEK2 and breast cancer risks 
CHEK2 is activated as an effector kinase when DNA damage occurs and is integral in 
signaling downstream repair proteins (Stracker, 2009). One of the most well-known mutations in 
CHEK2 is a founder mutation denoted as c.1100delC which was first described in 1999 in an 
individual who was suspected to have Li-Fraumeni syndrome (Bell, 1999). Founder mutations 
are ancient mutations found in individuals who share a common ancestor, and are therefore 
primarily unique to certain populations, in this case Western European populations. The 
1100delC variant was subsequently shown to be present in 5.1% of women with breast cancer 
who were confirmed to not harbor BRCA1/2 mutations (Meijers-Heijboer, 2002). In 2002, 
researchers published additional studies identifying CHEK2*1100delC as a “cancer 
susceptibility allele” (Consortium, 2002; Vahteristo, 2002). Following that discovery, the 
CHEK2 Breast Cancer Case-Control Consortium evaluated 10,860 cases and 9,065 controls from 
a number of studies, finding that the 1100delC allele conferred a two-fold increase in breast 
cancer risk (CHEK2 Consortium, 2004). Since then, multiple studies have characterized risks for 
both founder mutation carriers and non-founder mutation carriers. A study conducted in 2013 
indicated that women with CHEK2 mutations are at a 25-37% lifetime risk for developing breast 
cancer (Apostolou, 2013). A meta-analysis conducted by Easton et al in 2015, indicated that 
truncating variants in CHEK2 are “likely moderate penetrance,” conferring a three-fold relative 
risk and a 29% absolute risk by age 80 (p-value 8E-37) (CHEK2 breast cancer Case Control 
Consortium, 2004; Easton, 2015; Kilpivaara, 2004; Meijers-Heijboer, 2002; Weischer, 2012). 
The most recently published study providing a risk estimate for CHEK2 mutations predicted an 
odds ratio of 2.38 (p-value 3.66E-52) (LaDuca, 2020).  
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Data shows that breast cancer risks are similar between founder mutation carriers, such as 
c.1100delC, p.S428F, c.444+1G>A etc., and non-founder mutation carriers (Leedom, 2016). One 
should note, however, that location and type of variant may affect the lifetime risk provided to a 
patient. For instance, a CHEK2 missense variant, p.Ile157Thr, is associated with a lower breast 
cancer risk than the well-characterized c.1100delC variant, which is a truncating variant 
(Kilpivaara, 2004). This generalization is confounded by the fact that missense variants in highly 
conserved functional domains are likely to be associated with disease risk versus missense 
variants occurring in different, less evolutionarily conserved regions of the genes (Calvez-Kem, 
2011).  The NCCN Guidelines® for CHEK2 are “based only on frameshift pathogenic/likely 
pathogenic variants”; therefore, the risks for most missense variants remain uncertain at this time 
with the exception of variants such as Ile157Thr, which appears to have a lower breast cancer 
risk (NCCN, v1.2020). 
Data from multiple studies also demonstrate an increased risk for CBC among CHEK2 
1100delC carriers, with a range of associated risks spanning from a relative risk of 2.75 to 5.74 
and 10-year risks of CBC as high as 28.9% (Akdeniz, 2019; Broeks, 2004; De Bock, 2004; 
Kriege, 2014; Schmidt, 2007; Teoh, 2020). Another study shows no significant association 
between the 1100delC variant and rates of CBC (Mellemkjaer, 2008). 
d. NBN and breast cancer risks 
Akin to ATM, NBN was discovered to be a breast cancer susceptibility gene only after 
exploring its relation to an autosomal recessive genetic disease, Nijmegen Breakage Syndrome 1 
(NBS1) (Huang, 2008; Seemanova, 2007; Tauchi, 2002). NBS1 is associated with short stature, 
progressive microcephaly, a weakened immune system, increased risks of cancer, and 
intellectual disabilities, among other health problems (Varon, 1993). Among the moderate 
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penetrance breast cancer genes, perhaps the least is known about NBN. Much of what is known 
regarding NBN surrounds risks associated with the c.657_661del5 mutation, which has been 
observed in breast cancer, prostate cancer, medulloblastoma, and melanoma (Steffen, 2004; 
Ciara, 2010; Cybulski, 2004;). This specific deletion occurs in populations of Slavic descent and 
confers approximately a three-fold increase in breast cancer within these populations (Buslov, 
2005; Gorski, 2003, 2005; Steffen, 2004, 2006). 
In 2014, Damiola et al established that NBN is indeed an “intermediate-risk breast cancer 
susceptibility gene,” justifying its inclusion on cancer gene panels. Specifically, they showed that 
truncating variants and rare missense mutations in conserved areas of the gene confer a two to 
three fold increase in breast cancer risk (Damiola, 2014). Easton et al found that the protein-
truncating variant of NBN mentioned above, c.657del5, was found frequently enough in Eastern 
European populations to conduct a meta-analysis of 10 case control studies. They found that 
truncating variants likely confer a moderate penetrance relative risk of 2.7 (p-value 5E-7) and an 
absolute risk of 23% by age 80 (Easton 2015; Zhang, 2013). Bogdanova et al published data on 
the missense variant I171V, indicating that it is likely a “low-penetrance susceptibility allele for 
breast cancer,” but that a specific lifetime risk could not be predicted (Bogdanova, 2008). In this 
vein, the NCCN acknowledges that “current data suggest that breast cancer risks are not 
increased for pathogenic/likely pathogenic variants other than 657del5” (NCCN, v1.2020). For 
variants deemed pathogenic, LaDuca et al estimate the odds ratio for breast cancer to be 1.37 
(N=75818, p-value 0.0491) (LaDuca, 2020). 
There are no studies providing overall risk assessments for contralateral breast cancer in 
women with NBN mutations. 
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e. PALB2 and breast cancer risks 
PALB2, the “partner and localizer of BRCA2,” was originally discovered in 2006 while 
looking for BRCA2 associating complexes. It was implicated as a breast cancer susceptibility 
gene in 2007 when monoallelic truncation of PALB2 was shown to increase breast cancer risks 
by 2.3-fold (Rahman 2007; Xia 2006). A subsequent study conducted in 2011 showed between a 
two and four-fold increase in breast cancer risk, moving the needle up on risk estimates but 
ultimately calling for further research (Casadei, 2011). Two years later, Teo et al published their 
findings after analyzing Australasian families fraught with breast cancer. They concluded that 
about 1.5% families with multiple cases were attributable to protein truncations in PALB2, and 
supported clinical testing of PALB2 (Teo, 2013). In the wake of the Teo et al study, Catucci et al 
screened 575 Italian women from families with histories of breast cancer, finding that 2.1% had 
PALB2 mutations (Catucci, 2014). At that time, PALB2 was listed as a moderate-risk gene in 
breast cancer (Tischkowitz, 2010; Evans, 2014). 
However, given the shortage of large-scale PALB2 mutation data generated in the 
aforementioned studies, Antoniou et al embarked on a prospective international study to more 
accurately characterize PALB2 cancer risks. In a landmark study aiming to identify breast cancer 
risks based on monoallelic loss of function mutations in PALB2, Antoniou et al tracked 363 
women with PALB2 loss-of-function mutations from 154 families from age 20 until they were 
diagnosed with any cancer (primarily focusing on breast cancer), passed away, or turned 80 years 
old. Since this was a longitudinal study with a large, international study population, researchers 
were able to confirm or clarify previous estimations of cancer risk for mutation carriers. They 
found that breast cancer risks for PALB2 were up to nine times higher for PALB2 carriers 
younger than 40 years old, eight times as high for those between 40 and 60, and five times as 
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high for those over 60. Another important finding was that by age 70, female PALB2 carriers had 
a 35% chance of developing breast cancer (Antoniou, 2014).  
Antoniou’s study is extremely valuable to consider with regards to familial risk because the 
best fitting model it uses to categorize risks for PALB2 takes into consideration family history 
and affected first degree relatives. For instance, if a woman who tests positive for the PALB2 
mutation has no affected family members, her risk for breast cancer by age 70 is 33%; however, 
a woman who tests positive for PALB2 and has two first-degree relatives with breast cancer 
diagnosed by age 50 is at a 58% risk for developing breast cancer. These family factors should 
be considered with respect to medical decision making for women who have either affected 
family members, known PALB2 mutations, or both. 
Antoniou’s study is the gold standard for understanding risks for this population, but it was 
based on a specific group of those receiving diagnoses between 1930 and 2014, and the 
disparities of risk ratios based on which decade a woman was born are cause for skepticism—if 
their findings are correct, a woman’s risk factor if she was born in 1960 is 6.3 times as high than 
if she was born in 1940. After this critique, Antoniou et al acknowledged that their risk 
estimations could not be directly applied to patients (2014) seen in the clinic, pointing to the 
wide confidence intervals. The data collected for certain populations during Antoniou’s 
landmark study is also scant. Antoniou et al agreed that more research was needed for 
underrepresented populations, including those of Asian ancestry (Editorial, Antiniou, 2014). In a 
subsequent study of 100 Asian women seen in a high risk breast clinic, 4% presented with 
PALB2 mutations, warranting a closer look at this high frequency mutation in this population 
(Sopik, 2014). Contrary to Narod et al, Phuah et al had previously demonstrated that PALB2 
mutations are rare in multi-ethnic Asian populations and are not always associated with a family 
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history of breast cancer (Phuah, 2013). Most recently, a study of 7051 Japanese women with 
breast cancer and 11,241 controls identified a significant contribution to breast cancer risk from 
PALB2 in agreement with previously reported risks. In consideration of Phuah et al, Momozawa 
et al confirm PALB2’s role as a major hereditary breast cancer gene in Japanese women 
(Momozawa, 2018). Lower risks for a Finnish founder variant, c.1592delT have been 
demonstrated with case-control studies (Errko, 2007; Heikkinen, 2009). Yang et al also take into 
consideration 524 families with PALB2 mutations from 21 countries, providing country specific 
relative risks which are explained below (Yang, 2019). 
Both reviews and subsequent studies since Antoniou’s pivotal publication support the fact 
that Antoniou’s study is successful in determining breast cancer risks for women who have 
mutations in PALB2, though newer studies report slightly different risks (Wesola, 2017; Easton, 
2015; Yang, 2019). Easton et al conducted a meta-analysis to estimate the combined relative risk 
which was found to be 5.3 (CI=90%, 3.0 to 9.4) and a 45% absolute risk by age 80; therefore, 
“PALB2 mutations may fall into the high-risk category” which is defined as greater than or equal 
to four times the general population risk (Easton, 2015). There have been two studies published 
in 2020 that estimate the breast cancer risk for women with PALB2 mutations. LaDuca et al 
determined the odds ratio for PALB2 carriers as 5.1 (N=83862, p-value 1.89E-57). Yang et al 
report the relative risk for breast cancer to be 7.18 (95% CI, 5.82 to 8.85; p-value=6.5E-76), and 
to be declining with age with an estimated risk of 53% at age 80 for PALB2 carriers (Yang, 
2019). 
Antoniou’s study in 2014 became the impetus for researchers to investigate the frequency of 
PALB2 mutations across geographical locations and within subpopulations. In the Czech 
Republic, the frequency of PALB2 is high, up to 5.5% in a subgroup of hereditary breast cancer 
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patients (Janatova, 2016). Recurrent germline PALB2 mutations were found also in 7/460 (1.5%) 
of Polish women studied with breast cancer (Kluska, 2017). Notably, and as expanded upon 
below, these were recurrent mutations in the population which have the potential to be linked by 
origin. Finally, in Jamaica, which has the highest breast cancer rates in the Caribbean, 8 of 179 
(4.5%) breast cancer patients had a mutation in BRCA1 (1), BRCA2 (2) or PALB2 (5) (Lerner-
Ellis, 2017). 
PALB2 founder mutations have been identified in Finnish and French-Canadian populations. 
In Finland, the mutation discovered in approximately 1% of women with breast cancer 
irrespective of family history conferred a six times higher risk of breast cancer, approaching that 
of BRCA2 for the same population (Errko, 2007). Additionally, researchers discovered a founder 
mutation in about 0.5% of French-Canadian women with frequencies of up to 2.7% in women 
with early onset breast cancer who are also irrespective of family history. Breast cancer risk for 
this mutation was approximately 40% by age 70, and the researchers leading this study suggested 
that the highly penetrant PALB2 be added to breast cancer genetic testing panels (Foulkes 2007). 
Identical mutations found in certain populations and traced back also allow researchers to 
identify the origin on mutations. Such is the case for a common PALB2 mutation found in Polish 
families, suggesting that this particular mutation has origins in central Europe (Dansonka-
Mieszkowska, 2010). 
The PALB2 carrier frequency is estimated to be 0.08%, resulting in the estimation that 2.4% 
of all familial aggregation is due to these loss-of-function mutations (Antoniou, 2014). 
Accounting for all studies published until 2017, the occurrence rate of PALB2 mutation ranges in 
the population from 0.1% to 1.5% (Wesola, 2017). Clearly, both the frequency of PALB2 
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mutations and its penetrance for cancer vary widely between populations and researchers present 
consistently similar, but not always congruent, frequency and risk data for PALB2 mutations. 
There is currently no published literature on CBC risks in PALB2 carriers who have been 
diagnosed with breast cancer (Teoh, 2020; Song, 2018). 
 
F. Management of Moderate Penetrance Gene Carriers 
Similar to the management of BRCA1/2, management of moderate penetrance genes begins 
once a germline mutation has been identified in one of the moderate penetrance genes. The 
NCCN Guidelines® recommend that female carriers of ATM, CHEK2, and NBN undergo annual 
mammogram and consider breast MRI starting at age 40. Evidence for recommendations 
regarding RRMs is insufficient, so the guidelines recommend to manage “based on family 
history.” In other words, there currently exists insufficient evidence to provide guidance for risk 
reducing mastectomies for these moderate penetrance genes. Interestingly, at the outset of this 
study in 2019, the NCCN management recommendations (v.3.2019) for PALB2 were the same as 
ATM, CHEK2, and NBN, but recent publications offering a substantially higher lifetime risk for 
breast cancer in PALB2 carriers has shifted the suggested management. Specifically, guidance 
shifted from “RRM: Evidence insufficient, manage based on family history” in 2019 to “RRM: 
discuss option of risk-reducing mastectomy” in 2020 (v.1.2020). Based on large epidemiologic 
studies, the NCCN Guidelines® acknowledge that in general the value of RRMs in women with 
mutations in genes associated with a greater than two-fold risk without a significant family 
history of breast cancer is unknown. 
Management surrounding the treatment of women who have been diagnosed with cancer 
and harbor a moderate penetrance mutation is evolving and can be gene specific. For example, 
there was prior controversy as to whether women who have ATM mutations should receive 
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radiation therapy given associated ionizing radiation sensitivity, but recent studies indicate that 
decisions about radiation or systemic therapy should not be influenced by ATM carrier status 
(Jerzak, 2018). Another example is the use of PARP inhibitors as systemic therapy for certain 
gene mutation carriers. PARP inhibition has proven effective for eligible BRCA1/2 mutation 
carriers, but remains experimental for women harboring PALB2 mutations, which are involved in 
the same double strand break pathway as BRCA1/2, as well as both ATM and NBN mutation 
carriers (Macedo, 2019; Nielsen, 2016). Treatment considerations outside the scope of surgical 
approach are not fully considered in the current study. Gene-dependent management is further 
complicated by genotype-phenotype correlations of risk. For example, CHEK2 missense variants 
are not well-characterized so the NCCN Guidelines® suggest to manage patients “based on best 
estimates of cancer risk for the specific pathogenic/likely pathogenic variant” (NCCN, 2020). 
 
 
G. Decision Making Overview 
 
For the purposes of this manuscript, we make the distinction between two groups in 
decision-making: those who have been diagnosed with breast cancer and those who have not. 
Those who have not been diagnosed with breast cancer must make a decision about RRM given 
what they know about their own risks. Similarly, women diagnosed with breast cancer are faced 
with a decision to undergo CPM in addition to surgical management for the affected breast 
bearing in mind their risks. For both groups, a high-quality decision is one that is fully informed 
and aligned with one’s principles (Sepucha, 2004). Women who have higher perceived risks are 
more likely to undergo RRMs, though all determinants of perceived risks are not well known 
(Haroun, 2011; Hartmann, 2016; Meiser, 2003). The nexus of decision making is largely shaped 
by personal experiences which dominate analytic decision making. Diverse psychological, 
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social, and emotional factors complicate comprehension of genetic information (Heiniger, 2015; 
Hesse-Biber, 2016). Our study highlights what is known primarily about four surgical decision-
making elements: lifetime risk, family history, age, and marital status. 
 
H. Decision Making for Women Without Breast Cancer 
a. Overview 
Most of the literature regarding surgical decision making for gene mutation carriers is 
based on women who have been diagnosed with breast cancer. This imbalance in knowledge 
regarding surgical decision-making for unaffected women is more pronounced for moderate 
penetrance genes since there is currently much less published literature on these carriers as 
compared to BRCA1/2 carriers. A study published in February of 2020 by Napoli et al explores 
surgical decisions among women with mutations in moderate penetrance breast cancer genes, but 
of the 16 women included, just four were unaffected with breast cancer (Napoli, 2020). 
Nonetheless, the study is unprecedented and sheds an important light upon themes of robust 
decision making that vary between women with moderate penetrance mutations who are both 
unaffected and affected with breast cancer. This study by Napoli et al included semi-structured, 
qualitative interviews to determine decisional influences and themes among women with ATM, 
CHEK2, and PALB2 mutations, and offers unique patient perspectives. Two out of the four 
women without breast cancer chose to have RRM. For all four unaffected patients, decision-
making themes emerging from the semi-structured interviews included family history, physician 
opinions, risk perception, sibling influence, and health insurance. The authors of this study 
explain that presence of children or grandchildren was also a distinctive factor for how women 
decided to manage their risks, which conforms with other published literature (Stuckey, 2010; 
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Friebel, 2007; Skytte, 2010; Litton, 2009; Julian-Reynier, 2000; Napoli, 2020). RRM for 
unaffected BRCA1/2 carriers is dependent on an array of factors including country of origin and 
when a woman received genetic testing, among the many other factors mentioned above, which 
do not amount to an exhaustive list, nor provide evidence that the factors mentioned above are 
unequivocal in their influence (Henry, 2019; Metcalfe, 2008, 2009, 2019; Evans, 2019). 
b. Family History as an Influence for Unaffected Women 
Processing of the cancer experiences of relatives may influence surgical decision-making 
for an unaffected woman. The degree to which a woman “personally lived” the cancer 
experience of a relative is based on the amount of sharing of the cancer experience (e.g. 
closeness of woman and relative, developmental stage of women, and number/type of competing 
pressures), phase and variability of illness trajectory (emotional and social adjustments), and 
extent to which suffering was witnessed (Thomson, 1996).  
A family history of breast cancer is one of the strongest predictors breast cancer risk; 
however, women with BRCA1/2 mutations and a negative family history are still at a 
considerable lifetime risk for breast cancer: 60% by age 80, versus 63% for those with a family 
history of breast cancer (Pharoah, 1997; Metcalf, 2017). A study conducted by Singh et al on 
unaffected women at the same teaching hospital as this study population assessed rates of RRMs 
among 136 women with BRCA1/2 mutations. There was a significant uptake of RRMs for 
women with more total first and second-degree relatives who have been affected and who have 
died from breast cancer (Singh, 2013). If, for instance, a woman has a mother who passed away 
from breast cancer at a young age, she may request RRM at a younger age than is medically 
recommended. A family history significant for a first degree relative with breast cancer as well 
as higher total number of relatives with breast cancer have been associated with a higher 
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likelihood of choosing RRM versus surveillance (Henry, 2019). It’s worth noting that there’s the 
potential for these family factors to work in the opposite way as well—women who carry a 
deleterious mutation with little to no family history of breast cancer may perceive their risk as 
being lower than it actually is.  
c. Age as an Influence for Unaffected Women 
In general, unaffected younger women are more likely to undergo RRM than unaffected 
older women, which seems logical given that they have more of a risk to live through (Evans, 
2009, 2019; Hoskins, 2012; Metcalfe, 2008, 2019). One of the largest studies of BRCA1/2 
carriers found that 950 out of 3413 (27.8%) women without breast cancer had a RRM: the mean 
age was 41.8 and just 3.4% of mastectomies among this population were performed at age 60 
and above (Metcalfe, 2019). Perhaps a more relevant finding to this current study would be that 
3515 women including both those who were at a greater than 25% lifetime risk without known 
mutations and BRCA1/2 mutation carriers were assessed for RRM, and uptake was significantly 
related to younger age regardless of which group they were a part of (Evans, 2009). 
d. Marital Status as an Influence for Unaffected Women  
Although studies have assessed whether marital status influences surgical decision-
making for RRM, there has been no evidence to support that marital status significantly 
influences these decisions for unaffected women (Henry, 2019).  
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e. Lifetime Risk as an Influence for Unaffected Women 
There is also limited information surrounding whether lifetime risk alone influences 
surgical decision-making for unaffected women. The best comparisons can only be made 
between rates of two major groups of unaffected women that have been studied: BRCA1/2 
mutation carriers and those with no known mutations. In the United States, approximately 20% 
of BRCA1/2 carriers without breast cancer opt for RRM (Domchek, 2010; Printz, 2011).  In 
women who harbored no known mutation, 6.4% of women estimated at a 40-45% lifetime risk, 
2.5% of women estimated at 33-39% lifetime risk, and 1.8% of women at 25-32% lifetime risk 
elected for RRM (p-value=<0.005). Lifetime risks for this study were estimated similarly to our 
study, with the vast majority of unaffected women receiving lifetime risk estimates based on the 
Tyrer-Cuzick empiric risk model (Evans, 2009). The degree to which RRM reduces the risk of 
breast cancer differs between women with solely a positive family history of breast cancer and 
BRCA1/2 carriers. RRMs decrease a BRCA1/2 carrier’s lifetime risk by 90-95%, and RRMs 
decrease the risk of breast cancer in women with solely a family history by around 80%; 
therefore, women with BRCA1/2 mutations stand to benefit from a larger net risk reduction with 
a RRM (Metcalfe, 2008; Hartmann, 1999, 2001). 
 
I. Decision Making: CPMs for Breast Cancer Patients 
a. Overview 
Decision-making for patients became a focus in the 1980s, and subsequent legislation 
required “full disclosure of surgical options” for breast cancer patients. Since the 1980s, rates of 
mastectomy have sharply dropped from nearly 100 percent to about one-third for breast cancer 
patients today (Lerner, 2001; Lantz, 2002). The mortality for those choosing unilateral 
mastectomy versus breast conserving lumpectomy is equivalent (Habermann, 2010). Tumor 
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staging and location may hinder the use of breast conservation approaches, but most women 
remain candidates for Breast Conserving Surgery (BCS) (Morrow, 1998). Moreover, results from 
multiple studies suggest that there may be better quality-of-life outcomes, including positive 
body image, for women who choose lumpectomy versus unilateral mastectomy (de Haes, 2003).  
Patients overestimate their risks of CBC and the degree of risk reduction attained by 
CPM (Ager, 2016). With a substantial amount (43.9%) of women diagnosed with breast cancer 
considering CPM, it’s alarming that just 38.1% were aware that CPM does not improve overall 
survival (Jagsi, 2017). One study demonstrated that just 16% of breast cancer patients know that 
recurrence rates were not equivalent between mastectomy and lumpectomy and only 48% 
understood that the survival rates were equivalent between mastectomy and breast conservation 
surgery (BCS) with radiation (Fagerlin, 2006). Women with stage I and stage II breast cancer 
were studied, and overall women preferred a collaborative and active role over a passive role in 
decision-making for their treatment (Katz, 2007). Most women (88.1%) were pleased with their 
cancer treatment choice (Sabo, 2006). Nonetheless, the majority of patients frequently make 
decisions regarding surgery without accurate knowledge of the risks and benefits involved, 
which suggests that often times high-quality decisions are not being made with regards to 
surgery (Fagerlin, 2006). Luckily, most women are pleased with their selection of CPM; 
however, dissatisfaction with body appearance, femininity, and sexual relationships may be 
observed in some patients (Frost, 2005). 
Women opt for bilateral mastectomy based on a desire to avoid radiation, on how aggressive 
their disease is, on decreased need for surveillance, and on the fear of contralateral breast cancer 
or disease recurrence (Haberman, 2010; Rodby, 2016). Rates of unilateral mastectomies and 
CPMs have changed through time and have been shown to differ between regions and between 
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patients of different races, socioeconomic classes, smoking history, marital status, residence 
type, cancer stage and grade, and with different insurance coverage (Dores, 2010; Yakoub, 2014; 
Bhat, 2017; Metcalfe, 2019). Published data are not congruent on associations between these 
factors and decision-making, and there remains some uncertainty as to the factors that most 
influence decision making for breast cancer patients with regards to surgery. For example, Bhat 
et al analyzed bilateral mastectomy decisions for patients with unilateral breast cancer based on 
an array of factors including patient’s age, insurance status, urban versus rural residence, 
subsequent reconstruction, marital status, smoking history, family history of cancer, and cancer 
stage and grade. Patients who were less than 50, who had private insurance, who had residence 
in urban settings, and who planned for subsequent reconstruction were all more likely to undergo 
bilateral mastectomy versus unilateral mastectomy (Bhat, 2017). Another study observing rates 
of mastectomies from 1998 to 2013 found a six-fold increase in that time period. It was also 
found that rates of CPM positively correlated with younger, white, married, metropolitan, college 
educated and wealthier patients, while also finding, on the contrary, no correlation of CPMs with 
pathological characteristics including tumor stage and grade (You, 2018). A comprehensive 
literature review performed by Teoh et al indicates that CPM decision is based largely on a age, 
stage of disease, whether she has a genetic predisposition, whether family members have been 
diagnosed with breast cancer, fear of disease recurrence, desire for breast symmetry, and 
physician recommendations (Teoh, 2020; Bhat, 2017; Arrington, 2009; Buchanan, 2016; 
Brewster, 2011; Chung, 2012). Patients’ propensity to pursue mastectomies probably reflects 
uncertainty about the cancer they face and the treatment’s influence on their survival and well-
being (Katz, 2007). Those who are offered radiation or who are concerned about recurrence, for 
example, elect to undergo mastectomy more often (Sepucha, 2007). 
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In the aforementioned study conducted by Napoli et al exploring decision making among 
women with moderate penetrance gene mutations, four of twelve women with a personal history 
of breast cancer chose to have a RRM. Robust themes surrounding decision making for all breast 
cancer patients in this study included physician options, autonomy, sibling influence, family 
history, whether the woman had a breast cancer diagnosis, and perceived risk. Once again, our 
study highlights what is known primarily about four surgical decision-making elements: lifetime 
risk, family history, age, and marital status. 
b. Lifetime Risk as an Influence for Breast Cancer Patients 
As with unaffected women, presented lifetime risk for breast cancer patients has not been 
shown to play a significant role in a patient’s likelihood of pursuing RRM and reconstruction.  
c. Family History as an Influence for Breast Cancer Patients 
Family history can influence surgical choice for breast cancer patients. BRCA1/2 
mutation carriers with a first-degree relative diagnosed with breast or ovarian cancer are more 
likely to undergo RRM (Singh, 2013; Mæland, 2014). Furthermore, breast cancer patients who 
have had relatives with breast cancer are more likely to undergo CPM rather than BCS 
(Metcalfe, 2008; Haroun, 2011; Metcalfe, 2009). Other published research, on the contrary, did 
not find that family cancer history influenced decision making for unilateral versus bilateral 
mastectomy for breast cancer patients (Bhat, 2017). 
d. Age as an Influence for Breast Cancer Patients 
Patient age has been implicated as an independent predictor of surgical approach for 
breast cancer patients, though there exists discordance between studies. Some suggest that older 
patients trend towards undergoing RRM versus BCS (Chagpar, 2006; Lazovich, 1999; Nold, 
2000; Newcomb, 1993; Ward, 1989). In contrast, other studies show high rates of BCS in 
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patients in their 80s, an uptake of RRMs in women younger than 50, and still others found no 
statistically meaningful difference in age influencing BCS versus RRM (Rodby, 2016; Ballard-
Barbash, 1996; Bhat, 2017; Chapgar, 2006; Hussien, 2003; Hoskins, 2012).  
Age-specific breast cancer risk varies by gene, and thus the timing of preventative 
surgery should be discussed among women contemplating a RRM. For example, a RRM at age 
25 increased the probability of being alive at age 80 by 8.7% (from 42.7 to 51.3%) versus 2.8% 
at age 50 (from 42.7 to 45.5%) for BRCA1/2 mutation carriers. The consideration of RRM may 
therefore look much different for a BRCA1/2 carrier younger than 50, who stands to maximize 
risk-reduction benefits, versus a woman over age 50 (Giannakeas, 2018). 
Studies also suggest that age-related factors influence treatment plans for breast cancer 
patients, which influences the likelihood of pursuing RRM (Rodby, 2016). For example, age at 
diagnosis is an important consideration in disease feature and treatment—younger women 
typically present with more aggressive breast cancers which require chemotherapy and 
radiation—as well as surgical approach. Advances in radiation techniques may also factor into 
whether elderly patients are able to receive adjuvant radiation therapy, and therefore may impact 
decision making for BCS (Chapgar, 2006). 
Furthermore, age-dependent body habitus and breast shape factor into a woman’s 
decision to pursue RRM and reconstruction. Studies have suggested that older patients are less 
worried about cosmetic outcome and choose mastectomy versus BCS more often than younger 
patients who may have anatomical concerns such as desired breast shape, availability of tissue, 
and potential need for additional surgeries to achieve breast symmetry (Nold, 2000; Degner, 
1997). 
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e. Marital Status as an Influence for Breast Cancer Patients 
There are conflicting data on whether marital status of a woman influences her likelihood of 
undergoing a RRM, and Bhat et al did not find that marital status had a statistically significant 
impact on decision-making for unilateral versus bilateral mastectomies for breast cancers; 
however, other studies have shown increasing trends of CPM associated with married women 
(Bhat, 2017; You, 2018; Howard-McNatt, 2011). Napoli et al also describe that partners may 
have a greater influence for women affected with breast cancer due to the support they provide 
during the diagnosis process (Napoli, 2020). Marital status has been associated with decision-
making regarding breast reconstruction, with more women with relationship support of a 
marriage or partner undergoing reconstruction after mastectomy than women who were 
separated, single, or widowed. This study indicates only that relationship factors may influence-
decision making regarding post-surgery decisions, but does not verify anything about pre-surgery 
decision making. However, it is important to consider support networks of patients with and 
without breast cancer in tailoring preoperative counseling (Sergesketter, 2019). 
J. Objectives and Hypotheses 
The primary research objective of this study is to determine whether women with moderate 
penetrance gene mutations are influenced by their family history of breast cancer in their 
decision-making to undergo RRM. Our hypothesis is that women who have more first, second, 
and third degree relatives with breast cancer are more likely to undergo RRM across all risk 
stratified groups. Secondary research objectives include assessing whether presented lifetime risk 
of breast cancer, age, and marital status predict the likelihood of undergoing RRM across all 
three groups. We hypothesize that women presented with higher lifetime risks, younger women, 
and women in relationships are more likely to undergo RRMs. 
Running Head: MODERATE PENETRANCE RISK REDUCING MASTECTOMY RATES 
 
31 
MATERIALS AND METHODS 
 
A. Study Population 
 
See Table 1: Summary of Patient Demography by RRM Status 
 
After receiving approval from the CS-Investigational Review Board, we performed 
retrospective chart review of electronic medical records on a master list of patients seen through 
cancer genetics at an academic teaching hospital with genetic test results reported 6/1/2009 
through 6/1/2019. Data on each subject was collected at the time of her genetic test result. 
Eligible subjects include females at least 18 years of age with an available pedigree or 
family history on file, a documented management plan or surgical decision, and a known 
mutation status before any surgical decisions were made. Both breast cancer patients and women 
unaffected with breast cancer were included in this study population. 
Subjects with prior breast surgery before receiving genetic testing results, an unknown 
family history, stage 4 breast cancer, being actively treated for other cancers, or with breast 
cancer gene mutations other than those defining their study arm were excluded from eligibility. 
There are three arms of this study, each defined by cancer gene mutation status: moderate 
penetrance, high penetrance, and no known mutation. Those in moderate penetrance and high 
penetrance arms must have pathogenic variants or likely pathogenic variants, referred to as 
mutations in this paper, in the genes that define each arm as listed below. Only reports from 
Clinical Laboratory Improvement Amendments (CLIA) certified laboratories were included for 
entry into this study. 
The moderate penetrance arm contains 90 women with ATM, CHEK2, NBN, and PALB2 
mutations. 35 women from this arm were diagnosed with breast cancer. The high penetrance arm 
contains 98 women with BRCA1 and BRCA2 mutations. 30 women from this arm were 
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diagnosed with breast cancer. The no mutation arm contains 92 women with no known mutation. 
30 women in this arm were diagnosed with breast cancer. 
 
B. Study Instruments 
The master list of patients seen through cancer genetics at Cedars-Sinai Medical Center 
with variants in a number of genes and was created and populated by the team of genetic 
counselors at that institution and contains medical record number, first name, last name, date of 
birth, date of test result, laboratory at which testing was performed, name of test/panel, test 
results, gene, site of mutation, whether the subject was diagnosed with cancer, and ancestry for 
each subject. 
A Cedars-Sinai Utilization Report issued by Invitae was used to generate the no mutation 
status arm of this study and includes subjects who did not have a positive result on their testing 
panel. This report includes report release date, date of birth, requisition number, name of 
test/panel, ICD-10 Codes, and Cedars-Sinai genetic counselor contact for each subject at Cedars-
Sinai who underwent genetic testing through Invitae. The following testing panels were 
included: Invitae Breast and Gyn Cancers Guidelines-Based Panel, Invitae Breast and Gyn 
Cancers Panel, Invitae Breast Cancer Panel, Invitae Breast Cancer STAT Panel, Invitae Common 
Hereditary Cancers Panel, Invitae Common Hereditary Cancers Panel (Breast, Gyn, GI), Invitae 
Multi-Cancer Panel. 
A random integer generator through www.random.org allowed for collection of a 
systematic random selection of the positive and negative control groups. 
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The EPIC electronic medical record and Progeny pedigree tool were both used to locate 
subject data, which was abstracted and stored directly into a HIPAA-compliant REDCap 
electronic data portal.  
 
C. Data Collection 
The moderate penetrance was principal arm of interest and guided data collection for this 
study. The master list of genetic test results was filtered to include pathogenic and likely 
pathogenic variants in the genes of interest: ATM, CHEK2, NBN, and PALB2. This yielded a list 
of 203 potentially eligible subjects. Each was reviewed and 90 met eligibility criteria for this 
study after medical chart review. 
The high penetrance BRCA1 and BRCA2 arm was also populated using the same master 
list. Filtering the master list by BRCA1 and BRCA2 yielded a list of 300 potentially eligible 
subjects. A random integer generator was used to select a comparator group in a systematic 
random selection until 30 eligible subjects diagnosed with breast cancer and harboring BRCA1 
and BRCA2 mutations were gathered. 68 eligible women with BRCA1 and BRCA2 mutations 
who were not diagnosed with breast cancer were accrued in the process. 
The no mutation status arm was populated using the Invitae Cedars-Sinai Utilization 
Report. This report includes 813 potentially eligible subjects. A random integer generator was 
used to select a comparator group in a systematic random selection until 30 eligible subjects 
diagnosed with breast cancer were gathered. 62 eligible women with no mutation who were not 
diagnosed with breast cancer were accrued in the process. 
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Common reasons for ineligibility across all three arms include male sex, previous 
surgery, active treatment for another cancer, stage 4 breast cancer, multiple mutations, and 
insufficient records. 
The following data was collected for each subject:  
1. Demographics: age, ethnicity, race, sex, marital status 
2. Mutation status: CLIA lab certified result, gene, variant information date of report 
3. Breast Cancer Risk: breast cancer lifetime risk for unaffected women, age at which 
lifetime risk provided, method by which lifetime risk calculated. 
4. Personal History: breast cancer diagnosis, age of diagnosis if diagnosed, type of breast 
cancer if diagnosed, stage of breast cancer if diagnosed, whether subject was diagnosed 
with any other type of cancer, type of other cancers if diagnosed and age at which 
diagnosed. 
5. Family History: whether first, second, and third degree relatives were diagnosed with 
breast cancer, how many of each were diagnosed, relation to the subject (i.e. mother, aunt 
etc.), ages of diagnoses, age passed away, if applicable. 
6. Surgical Decision: recommendation for surgery, reason for surgical recommendation, 
surgical decision, age surgical decision made, motivation for surgery 
7. Previous Genetic Testing: whether subject previously underwent genetic testing, years 
since testing, whether subject previously underwent genetic counseling, years since 
genetic counseling 
8. Children Status: whether the subject has children, how many children the patient has, 
ages of children 
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D. Data Analysis 
Demographic categories were separated by “No RRM” and “RRM” among the study 
population and were compared using independent samples t-tests or chi square tests of 
independence, where appropriate. See Table 1.  
Logistic Regression Models were run on each research question, producing odds ratios 
based on exposure versus outcome. The exposures retrospectively analyzed were number of 1st, 
2nd, and 3rd degree relatives with a history of breast cancer, presented lifetime risk, age, and 
marital status. Outcome in our model was whether the patient received a RRM or did not receive 
a RRM. For this study, “bilateral mastectomy” for unaffected and affected subjects was 
considered RRM. For affected patients, a unilateral mastectomy was not considered a RRM. 
Family history was separated into 6 models, which were created based on mutation status 
and whether the patient had breast cancer at the time of surgical decision. Within each model 
odds ratios were assessed independently by degree of relative. See Table 2. 
Remaining lifetime risk of breast cancer was collected solely for those women who did 
not have a diagnosis of breast cancer. Chart abstraction yielded percentage values for remaining 
lifetime risk that each patient was presented during their decision making period. When ranges 
were provided, the mean value of the two numbers was used. See Table 3 and 4. 
The age at time of surgical decision was analyzed as an exposure. See Table 5. 
Logistic regression models for marital status were conducted with “Married/Unmarried” 
couple as the reference group, and “Never married” and “Divorced/Separated/Widowed” as 
groups illustrating the effects of marital status on decision making. The rationale for combining 
“widowed” with the divorced/separated stems from the fact that each subject in this group once 
had a partner’s support and no longer have that partner’s support. See Table 6. 




A. Patient Demographics 
Patient demographics are listed in Table 1. The groups comprising the risk stratified groups 
were fairly balanced: 32.9% had no known risk mutations, 32.1% had moderate penetrance gene 
mutations, and 35% had BRCA mutations. Most of the subjects included in this study were non-
Hispanic, white (78.1%). The average age at which surgical decision was made was 45.7 years. 
For patients who were diagnosed with breast cancer, most were diagnosed with IDC (70.5%) and 
most were either stage 1 or 2 breast cancer (77.9%). Most patients in this study did not have 
previous genetic counseling (97.4%) or genetic testing (93.5%). Documented surgical decisions 
vary between women with and without breast cancer and are shown in Figure 1 and Figure 2. 
The average number of first, second, and third degree relatives with breast cancer was not 
shown to independently influence surgical decision making for this study population. 
There were statistically significant differences between RRMs and no RRMs for the 
following categories: age of diagnosis, marital status, mutation status, and whether a patient was 
diagnosed with breast cancer.  
For breast cancer patients, women who underwent RRM were on average 13.2 years younger 
at age of diagnosis than those who didn’t undergo RRM (45.7 vs 58.9).  
Women who have never been married underwent RRM less often than the other two marital 
status groups. 15.9% (14/88) of women who were never married underwent RRM, while 31.1% 
(53/170) of women who were either married or in a relationship underwent RRM. 31.8% (7/22) 
who were either divorced, separated, or widowed underwent RRM, but the sample size for this 
group was relatively small compared to the other two groups. 
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For both women with and without breast cancer, rates of RRM increased with mutation status 
stratification. 8.6% (8/92) of women with no known risk mutations, 30% (27/90) of moderate 
penetrance gene carriers, and 39.8% (39/98) of BRCA mutation carriers underwent RRM. 
Finally, rates of RRM were higher among women who were diagnosed with breast cancer. 
56.8% (54/95) of women with breast cancer underwent RRM while 10.8% (20/185) of women 
who were unaffected underwent RRM. The breakdown of mutation status stratification among 
these women with breast cancer is demonstrated in Figure 2.  
 





Summary of Patient Demography by RRM Status (n = 7 - 279) 
 Overall  No RRM  RRM  
Demographics M (SD) Freq (%)  M (SD) Freq (%)  M (SD) Freq (%) p* 
Age Surgical Decision Made 45.7 (14.6)   45.8 (16.0)   45.2 (10.0)  .71 
Age Dx (if applicable) 51.4 (12.8)   58.9 (12.9)   45.7 (9.3)  < .001 
Race/Ethnicity         .87 
Asian/API  21 (7.5)   13 (61.9)   7 (33.3)  
Black/African American  12 (4.3)   9 (75)   3 (25)  
White, Hispanic   9 (3.2)   6 (66.7)   3 (33.3)  
White, Non-Hispanic Latino  218 (78.1)   57 (26.1)   161 (73.9)  
Other  19 (6.8)   15 (78.9)   4 (21.1)  
Marital Status         .02 
Never Married  88 (31.4)   74 (84.1)   14 (15.9)  
Married/Unmarried Couple  170 (60.7)   117 (68.8)   53 (31.2)  
Divorced/Separated/Widowed  22 (7.9)   14 (63.6)   7 (31.8)  
Mutation Status         < .001 
No known risk mutations  92 (32.9)   84 (91.3)   8 (8.7)  
Moderate penetrance  
(ATM, CHEK2, NBN, PALB2) 
 90 (32.1)   63 (70)   27 (30)  
BRCA1/2  98 (35.0)   58 (59.2)   39 (39.8)  
Diagnosed with breast cancer         < .001 
Yes  95 (33.9)   41 (43.2)   54 (56.8)  
No  185 (66.1)   164 (88.6)   20 (10.8)  
Breast Cancer Type          .24 
Mixed DCIS and IDC  5 (5.3)   1 (20)   4 (80)  
DCIS  15 (15.8)   8 (53.3)   7 (46.7)  
IDC  67 (70.5)   26 (38.8)   41 (61.2)  
ILC                                           4 (4.2)   3 (75)   1 (25)  
Other  4 (4.2)   3 (75)   1 (25)  
Stage of Breast Cancer         .38 
0  15 (15.8)   8 (53.3)   7 (46.7)  
1  39 (41.1)   17 (43.6)   22 (56.4)  
2  35 (36.8)   12 (34.3)   23 (65.7)  
3  6 (6.3)   4 (66.7)   2 (33.3)  
Number of Relatives with Breast 
Cancer 
         
1st Degree 1.2 (0.5)   1.2 (0.5)   1.3 (0.6)  .43 
2nd Degree 2.2 (5.6)   2.0 (4.6)   2.9 (7.7)  .39 
3rd Degree 1.4 (0.8)   1.4 (0.7)   1.5 (0.9)  .45 
Previously Received Genetic 
Counseling         .30 
Yes  7 (2.6)   4 (57.1)   3 (42.9)  
No  263 (97.4)   195 (74.1)   67 (25.5)  
If yes, years since 0.03 (0.2)   5.8 (2.2)   4.3 (5.8)  .67 
Previously Received Genetic Testing         .22 
Yes  18 (6.5)   11 (61.1)   7 (38.9)  
No  261 (93.5)   193 (73.9)   67 (25.7)  
If yes, years since 7.7 (4.7)   8.8 (5.0)   6.0 (4.1)  .33 
* Comparisons between “No RRM” and “RRM” using independent samples t-tests or chi square tests of 
independence, where appropriate. 
One participant’s RRM status was listed as “unknown” and was excluded from the “No RRM” and “RRM” columns 
 
 





Surgical Decisions among Women without Breast Cancer: For the no mutation group, 
one subject (1/62; 1.61%  stated that she was considering a future RRM and 98.39% (61/62) 
decided against RRM. For the moderate penetrance arm, 13.46% (7/52) received a RRM, 
23.08% (12/52) were considering a future RRM, and 63.46% (33/52) elected to not undergo 
RRM. Finally, for the BRCA1/2 group 10.45% (7/67) underwent RRM, 31.34% (21/67) indicated 
that they were considering a RRM in the future, and 49.25% (33/67) decided against RRM. 
Subjects whose surgical decision was listed as “other” (N=3) and whose surgical decision was 



















No Mutation (N=62) Moderate Penetrance (N=52) BRCA1/2 (N=67)
Surgical Decisions among Women without Breast 
Cancer (N=181)
RRM Considering Future RRM No Surgery





Surgical Decisions among Women with Breast Cancer: For the no mutation group, 29.03% 
(9/31) elected for bilateral mastectomy, 51.61% (16/31) elected for lumpectomy, and 19.35% 
(6/31) elected for a unilateral mastectomy. For the moderate penetrance group, 58.82% (20/34) 
underwent bilateral mastectomy, 35.29% (12/34) received a lumpectomy, one (2.94%) received a 
unilateral mastectomy, and of note, there was one breast cancer patient who declined surgical 
treatment.  For the BRCA1/2 group, 86.67% (26/30) elected to undergo bilateral mastectomy and 
13.33% (4/30) received a lumpectomy. One patient whose surgical decision was listed as 
“Considering future mastectomy” was excluded from this figure. 
 
 
B. Family History and RRM Odds Ratios 
 
A series of multiple logistic regression models were conducted in order to determine whether 
the number of first, second, and third degree relatives with a history of breast cancer influences 
the odds of undergoing a RRM 1) among patients with mutations in BRCA1/2, 2) among patients 




















No Mutation (N=31) Moderate Penetrance (N=34) BRCA1/2 (N=30)
Surgical Decisions among Women with Breast Cancer 
(N=95)
Bilateral Mastectomy (RRM) Lumpectomy Unilateral Mastectomy No Surgery
Running Head: MODERATE PENETRANCE RISK REDUCING MASTECTOMY RATES 
 
41 
with no known mutation. Whether or not the patient had breast cancer was also taken into 
account. As shown in Table 2, the number of relatives with a history of breast cancer served as a 
statistically significant predictor of undergoing RRM in just a single model (see Model 3; 2 (3) = 
25.30, p < .001, Nagelkerke’s R2 = .69, Cox & Snell R2 = .37). Specifically, among patients without breast 
cancer who tested positive for a mutation in moderately penetrant genes (ATM, CHEK2, NBN, or 
PALB2), the odds of undergoing RRM increased over a hundredfold per first degree relative with 
a history of breast cancer. 
 
 








Summary of Logistic Regression Models of Number of 1st, 2nd, and 3rd Degree Relatives with History of 
Breast Cancer on Odds of Undergoing RRM (n = 30, 55, 35, 67, 30) 
Variable B SE B Exp (B) p 
Model 1: No breast cancer; no known mutations 
Model could not be run; RRM is a constant (i.e. no subjects underwent RRM) 
Model 2: Breast cancer; no known mutations  
Constant -1.30 0.67 0.27  
1st Degree Relatives with History of BC -0.001 0.68 1.00 .99 
2nd Degree Relatives with History of BC -0.06 0.54 0.94 .91 
3rd Degree Relatives with History of BC 1.33 0.99 3.79 .18 
Model 3: No breast cancer; moderate penetrance genes (ATM, CHEK2, NBN, and PALB2) 
Constant -9.37 3.52 0.00  
1st Degree Relatives with History of BC 4.65 2.10 104.82 .03 
2nd Degree Relatives with History of BC 2.00 1.20 7.37 .10 
3rd Degree Relatives with History of BC 0.91 0.72 2.47 .21 
Model 4: Breast cancer; moderate penetrance genes (ATM, CHEK2, NBN, and PALB2) 
Constant 0.003 0.50 1.00  
1st Degree Relatives with History of BC -0.46 0.93 0.63 .62 
2nd Degree Relatives with History of BC 1.02 0.56 2.77 .07 
3rd Degree Relatives with History of BC -0.68 0.56 0.51 .22 
Model 5: No breast cancer; BRCA 1/2 
Constant -1.82 0.59 0.16  
1st Degree Relatives with History of BC 0.67 0.39 1.95 .09 
2nd Degree Relatives with History of BC -0.31 0.39 0.74 .43 
3rd Degree Relatives with History of BC 0.37 0.49 1.44 .35 
Model 6: Breast cancer; BRCA 1/2a 
Constant 1.74 0.68 5.68  
1st Degree Relatives with History of BC -0.19 1.29 0.83 .88 
2nd Degree Relatives with History of BC 0.25 0.66 1.28 .71 
Overall model statistics, Model 2: c2 (3) = 1.93, p = .59, Nagelkerke’s R2 = .09, Cox & Snell R2 = .06 
Overall model statistics, Model 3: c2 (3) = 25.30, p < .001, Nagelkerke’s R2 = .69, Cox & Snell R2 = .37 
Overall model statistics, Model 4: c2 (3) = 5.28, p = .15, Nagelkerke’s R2 = .18, Cox & Snell R2 = .14 
Overall model statistics, Model 5: c2 (3) = 5.05, p = .17, Nagelkerke’s R2 = .12, Cox & Snell R2 = .07 
Overall model statistics, Model 6: c2 (2) = 0.44, p = .80, Nagelkerke’s R2 = .03, Cox & Snell R2 = .02 
a Note: Due to a radically inflated SE and Exp (B) attributable to limited sample size, 3rd degree relatives were 
omitted from Model 6 
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C. Lifetime Risks and RRM Odds Ratio 
 
In order to determine whether lifetime risk of breast cancer estimates influence the odds of 
undergoing a RRM among patients without breast cancer, a simple logistic regression model was 
run. As shown in Table 3, lifetime risk of breast cancer estimates did serve as a statistically 
significant predictor of the odds of undergoing RRM (2 (1) = 7.94, p = .005), with the odds of 
undergoing a RRM increasing 1.03 times per percentage point of lifetime risk. While the results 
were statistically significant, lifetime risk of breast cancer estimates were modest predictors of 
patients’ actual behaviors, explaining only approximately 5-10% of the observed variability in 
RRMs (Nagelkerke’s R2 = .10, Cox & Snell R2 = .05). Average lifetime breast cancer risks and 








Summary of Logistic Regression Model of Lifetime Risk Estimate on Odds of Undergoing RRM (n = 185) 
Variable B SE B Exp (B) p 
Constant -3.57 0.67 0.03  
Lifetime Risk 0.03 0.01 1.03 .006 














Average Lifetime Risk (SD) 20.25 (7.34) 32.27 (11.70) 63.69 (17.30) 
Average Age at Results Disclosure (SD) 44.21 (13.44) 44.02 (12.14) 34.66 (11.74) 
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D. Patient Age and RRM Odds Ratio 
 
In order to determine whether age at time of surgical decision influences the odds of 
undergoing a RRM, a simple logistic regression model was run. As shown in Table 5, age at time 
of surgical decision failed to statistically significantly predict the odds of undergoing RRM (2 (1) 







Summary of Logistic Regression Model of Age at Time of Surgical Decision on Odds of Undergoing RRM 
(n = 280) 
Variable B SE B Exp (B) p 
Constant -0.88 0.45 0.41  
Age at Time of Surgical Decision -0.003 0.01 1.00 .76 
Overall model statistics: c2 (1) = 0.09, p = .76, Nagelkerke’s R2 < .001, Cox & Snell R2 < .001 
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E. Marital Status and RRM Odds Ratios 
In order to determine whether marital status influences the odds of undergoing a RRM, a 
simple logistic regression model was run. As shown in Table 6, marital status did serve as a 
statistically significant predictor of the odds of undergoing RRM (2 (2) = 7.96, p = .02), with the 
odds of undergoing a RRM being 0.42 times as likely for never married patients compared to 
married/unmarried couples. While the results were statistically significant, marital status was a 
modest predictor of patients’ actual behaviors, explaining only approximately 3-4% of the 




Summary of Logistic Regression Model Marital Status on Odds of Undergoing RRM (n = 279) 
Variable B SE B Exp (B) p 
Constant -0.79 0.17 0.45  
Never Marrieda -0.87 0.34 0.42 .01 
Divorced/Separated/Widoweda 0.10 0.49 1.10 .84 
Overall model statistics: c2 (2) = 7.96, p = .02, Nagelkerke’s R2 = .04, Cox & Snell R2 = .03 
a Reference Category: Married/Unmarried Couple 
 





Women who have access to genetic counselors are provided more thorough information 
about risk and prevention and are more supported to process information and make decisions 
(Padamsee, 2017; Connors, 2014). All of the women in this study had access to genetic 
counseling, yet women’s risk perceptions differ greatly than those of healthcare providers 
(Salant, 2006; Hesse-Biber, 2014). Clarity on decisional facets explored in this study may assist 
providers in better understanding the perceived risks of their patients and ultimately facilitate 
informed decision making. 
B. Family History 
Assessing RRM rates in regard to family history and in the context of gene mutation status 
proved valuable to draw comparison between what was observed on a study population level 
versus within subgroups, especially moderate penetrance gene carriers. Although potentially 
attributable to modest sample size in each model, the only statistically significant predictor of 
undergoing a RRM was the presence of affected first degree relatives, and only for unaffected 
moderate penetrance gene carriers. Perhaps these women, in the absence of pressure from a 
breast cancer diagnosis or high penetrance mutation, turn to shared experiences of their sisters or 
mothers in their decision-making. In other studies, presence of first degree relatives, especially 
sisters, as well as a higher number of total relatives with breast cancer has been shown to 
increase the rates of RRM among both BRCA1/2 carriers and in a cohort combining high and 
moderate penetrance gene carriers (Henry, 2019; Metcalfe, 2008). This current study did not 
assess decision making in the context of the total number of affected relatives; however, number 
of first, second, and third degree relatives separately did not increase the odds of RRM for the 
entire study population. This study is novel in illuminating the effect of family history 
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independently within genetic risk stratified groups and has shown that family history influences 
surgical decision making for moderate penetrance gene carriers. 
C. Lifetime Risk 
 
As predicted, lifetime risk presented to unaffected patients at time of results disclosure 
was a statistically significant predictor of decision to undergo RRM. Surprisingly, however, 
higher lifetime risks only modestly increased the odds of undergoing RRM, increasing 1.03 
times per percentage point and thus explaining only 5-10% of variability in RRMs. This may 
explain why there were similar rates in RRM between unaffected moderate penetrance carriers 
and unaffected BRCA1/2 carriers in this cohort. It may also explain the similar rates of women 
considering future RRM between the same two groups. For unaffected women in this study, the 
average presented lifetime risk was 20.25% for no mutation carriers, 32.27% for moderate 
penetrance carriers, and 63.69% for BRCA1/2 carriers. The American Cancer Society 
recommends that all women with a greater than 20% lifetime risk of breast cancer undergo a 
breast mammogram and a breast MRI every year. Average lifetime risks for each of these groups 
cross this “high-risk” threshold, yet evidently mutation status itself may be a stronger predictor 
than actual presented lifetime risk given the rates of RRMs in this unaffected group of women. 
Intriguingly, the average ages of presentation of this lifetime risk were the same for the no 
mutation group and moderate penetrance group, and average lifetime risk differed only by 12%; 
however, not a single unaffected no mutation carrier underwent RRM. Surprisingly, the rates of 
RRM between moderate penetrance and BRCA groups were similar despite the fact that lifetime 
risk of breast cancer is 30% higher in the BRCA group than in the moderate penetrance group. It 
should be noted, however, that the average age of women in the BRCA1/2 group when presented 
with their lifetime risk was 10 years younger than the moderate penetrance group (Table 4). It 
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might be that younger women in this group are less inclined to undergo an RRM even though the 
literature suggests that younger women who are unaffected with breast cancer are more likely to 
undergo RRM than unaffected older women since they stand to gain a higher net risk reduction 
with a RRM (Evans, 2009, 2019; Hoskins, 2012; Metcalfe, 2008, 2019). 
D. Age 
 
Age has been contended as a decisional influencer for RRM for women with breast 
cancer (Ballard-Barbash, 1996; Bhat, 2017; Chagpar, 2006; Hoskins, 2012; Hussien, 2003; 
Lazovich, 1999; Nold, 2000; Newcomb, 1993; Rodby, 2016; Ward, 1989). However, literature 
suggests that younger women who are unaffected with breast cancer are more likely to undergo 
RRM than unaffected older women (Evans, 2009, 2019; Hoskins, 2012; Metcalfe, 2008, 2019). 
This current study found no relationship between surgical decision and age, but included a 
combined cohort of unaffected (N=185) and affected (N=95) women. Our hypothesis that 
younger women across both groups would elect to undergo RRM more than older women was 
founded upon the principle that a greater net reduction in risk of a future diagnosis of breast 
cancer was attainable at a younger age. This consideration is seemingly eclipsed by other 
decision making factors such as marital status for women in this study. 
E. Marital Status 
 
Having a partner purportedly has a greater influence on RRM decision making for 
women affected with breast cancer than those not facing a diagnosis due to the support partner 
provides during the diagnosis process (Napoli, 2020). It is, however, crucial to consider support 
networks of patients both with and without cancer in the preoperative counseling period since no 
studies to date have indicated that marital status either increases or decreases the rates of RRMs 
among unaffected high risk women. The findings of this study in regard to marital status did not 
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draw a comparison between affected and unaffected women, but suggest that women who have 
never been married are 0.42 as likely to undergo RRM than women who are either married or in 
a relationship. Once again, marital status was only a modest predictor of RRM rates. This could 
be a matter of support network, as previously implied, but one cannot rule out other competing 
factors such as age-dependent body habitus and desired cosmetic outcome which have been 
shown to influence surgical decision making (Nold, 2000; Degner, 1997). For this study 
population, women in relationships were older by 11 years on average than single women 
(M(SD)= 48 (13.24) vs. 37 (13.02)) and while age at time of surgical decision-making did not 
influence the odds of undergoing a RRM for the entire study population, the difference in ages 
between these two marital status groups cannot be ruled out as a potential confounding variable. 
Women may also think that RRM may adversely impact their likelihood of finding a future 
partner or prevent them from breastfeeding, though these factors are at this point conjectures in 
light of the scope of this study and currently published research. 
 
F. Limitations:  
 
Many of the limitations of this study stem from it being a retrospective study looking solely 
at patients at one academic hospital in an urban setting. The patient population, like so many 
others, constituted majority Non-Hispanic white women and underrepresents the general 
population demographics. It’s reported that women located in urban residence are more likely to 
undergo RRM with an odds ratio of 2.22, so total RRM rates may be higher compared with other 
settings (Bhat, 2017). This study population comes from one center in the US, and researchers 
have shown that rate of RRM differs by country (Metcalfe, 2019).  
Additionally, chart abstraction by nature is imperfect. For example, it may be impossible to 
know whether a woman was truly considering a RRM if she did not tell the genetic counselor or 
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if it was not documented in the clinic note within the EMR. Comprehensive searches of EMRs 
may yield no results as to whether a surgery occurred, and assumptions are made that if a 
subject’s intentions towards surgery were not explicitly noted and she had no follow up with 
surgeons within the medical network or EMR-collaborators, that she ultimately decided to not 
undergo surgery at that time. Exhaustive risk factors were not collected for gene mutation 
carriers, though some were integrated with empiric risk models for non-mutation carriers using 
Tyrer-Cuzick. For example, it was not captured whether a woman received a risk reducing 
salpingo-oophorectomy, whether she breast fed, age of menarche, etc., which have been shown 
to impact BRCA1 carriers (Kotsopoulos 2018). In the same vein, presented remaining lifetime 
risks may be inaccurate based on insufficient data, especially for moderate penetrance gene 
carriers. For example, Tyrer-Cuzick produces a remaining lifetime risk based on the current age 
of a woman, and currently age-related risks are more unclear for mutation carriers such as those 
with NBN mutations. Discussions in clinic may take a woman’s age into consideration, but may 
not be reflected in clinician notes. For example, a woman identified to have a NBN mutation may 
be told in clinic, “women with a NBN mutation are at a two to four fold increase risk for breast 
cancer over their lifetimes, but since you’re 65, you’ve outlived a substantial portion of this 
risk,” but the note may include solely the first portion of this compound sentence.  
There are analytical limitations given how subjects were grouped in this study. For example, 
many decision-making variables were assessed in a combined cohort of affected and unaffected 
women. As stated previously, decision-making factors such as age and possibly marital status 
have been shown to be dependent on whether a woman has a breast cancer diagnosis. In addition, 
models of family history and breast cancer subdivide influences of first, second, and third degree 
relative on odds of undergoing RRM, but total number of relatives affected with breast cancer is 
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not assessed in these models nor across the entire study population. Data also shows that whether 
a woman has children may influence her odds of undergoing RRM. While collected, this study 
did not analyze whether a woman with children was more likely to undergo a RRM. 
 
G. Future Research 
 
The completion of this study leaves more questions unanswered than answered. The 
limitations of analyzing research questions regarding age and marital status with combined 
cohorts of unaffected and affected women is that we still don’t know whether marital status is 
dependent upon whether a woman is affected or not. The findings that marital status is a modest 
predictor of patient behavior warrants further investigation into whether this is primarily in the 
context of a new diagnosis. Additionally, women may also think that RRM may adversely 
impact their likelihood of finding a future partner or prevent them from breastfeeding. This is 
something that should be explored further qualitatively. A prospective study designed to assess 
decision-making factors of women found to harbor breast cancer susceptibility gene mutations 
would illuminate reasons for the observed rates of RRM among women considered at high risk. 
Eventually, understanding these factors may open the door for interventions and educational 
tools to better inform patients in their decision making process. 
 
  





Women identified to have a higher risk for developing breast cancer choose whether to 
have a RRM, and make this decision based on a number of factors. This retrospective study of 
280 women demonstrates that mutation status, breast cancer diagnosis, and age of diagnosis 
influence decision making for RRM for women with no mutations, moderate penetrance 
mutations, and BRCA1/2 mutations. Unaffected moderate penetrance carriers who had first 
degree relatives with breast cancer were significantly more likely to undergo RRM, but family 
history otherwise didn’t influence decision making for the entire study population. Lifetime risks 
presented to unaffected women and marital status for all patients were both modest predictors of 
subjects’ propensity to undergo RRM, and age did not influence the odds of undergoing RRM. 
As healthcare providers, we should continue to strive to understand decisional influences so that 
we can support patients in informed decision making. 
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